Provention Bio to Report Third Quarter 2022 Financial Results on November 3, 2022

Rhea-AI Summary

Provention Bio, Inc. (Nasdaq: PRVB) announced it will report its third quarter 2022 financial results on November 3, 2022, before U.S. market opening. A conference call is scheduled for 8:00 AM E.T. to discuss results and provide updates. The company focuses on developing therapies for immune-mediated diseases, with its lead drug candidate, teplizumab, having a Biologics License Application filed with the FDA for delaying progression of Stage 3 clinical type 1 diabetes. Investors are encouraged to monitor the company’s website for updates.

RED BANK, N.J., Oct. 13, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its third quarter 2022 financial results on Thursday, November 3, 2022, before the opening of the U.S. financial markets. The company will host a conference call at 8:00am E.T. to discuss its financial results and provide a company update.

To access the call, please dial 1-888-347-7861 (domestic) or 1-412-902-4247 (international) ten minutes prior to the start time and ask to be connected to the "Provention Bio Call." An audio webcast will also be available on the "Events and Webcasts" page of the Investors section of the Company's website, www.proventionbio.com. An archived webcast will be available on the Company's website approximately two hours after the conference call.

About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay of progression to Stage 3 clinical type 1 diabetes in at-risk individuals has been filed by the U.S. Food and Drug Administration (FDA). The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.

Internet Posting of Information
Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

Investor Contact:

Kristen Kelleher, Investor Relations
investorrelations@proventionbio.com

Media Contact:

Kaelan Hollon, VP of Communications
khollon@proventionbio.com 
202-421-4921

View original content to download multimedia:https://www.prnewswire.com/news-releases/provention-bio-to-report-third-quarter-2022-financial-results-on-november-3-2022-301646538.html

SOURCE Provention Bio, Inc.

FAQ

When will Provention Bio report its third quarter 2022 financial results?

Provention Bio will report its third quarter 2022 financial results on November 3, 2022.

What time is the Provention Bio conference call?

The Provention Bio conference call is scheduled for 8:00 AM E.T. on November 3, 2022.

What is the focus of Provention Bio?

Provention Bio is focused on developing therapies for immune-mediated diseases.

What is teplizumab?

Teplizumab is Provention Bio's lead investigational drug candidate aimed at delaying progression to Stage 3 clinical type 1 diabetes.